TScan Therapeutics appoints Jason A. Amello as CFO effective Jan 29, 2024

TScan Therapeutics, Inc.

Jason A. Amello appointed CFO effective January 29, 2024; previously CFO at Candel Therapeutics, Akebia, and Saniona.
Base salary of $500,000 per annum, one-time payment of $60,000, option for 750,000 shares vesting over 4 years.
Eligible for discretionary bonus target up to 40% of base salary; severance and change-of-control provisions consistent with non-CEO executives.
Prior interim CFO responsibilities held by CEO Gavin MacBeath and VP Finance Leiden Dworak cease as of Start Date.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason A. Amello

Chief Financial Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2024-01-29
Filed: January 29, 2024, 6:59 PM ET

On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jason A. Amello was appointed as Chief Financial Officer at TScan Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”).

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-017379

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.